

MaxCyte Inc

16:27 30 Sep 2019

MaxCyte to make five presentations before the year-end on groundbreaking CARMA system

MaxCyte Inc (LON:MXCT) said it is taking part in five industry conferences at which it will showcase its CARMA technology.

The platform can rapidly produce cell therapies taking one day where traditional methods might take one to two weeks.

It is used by some of the world's largest drug companies, and CARMA is at the heart of around 70 clinical and pre-clinical programmes.

MaxCyte also used the system to develop its lead drug candidate, MCY-M11, which is currently in phase I trials with people suffering advanced ovarian cancer and peritoneal mesothelioma.

Below are the industry forums at which MaxCyte will present:

ESMO Congress 2019

27 September-1 October 2019, Barcelona, Spain

This is a poster later Monday (today) by Christina Annunziata looking at MCY-M11

Cell & Gene Meeting on the Mesa

2-4 October 2019, Carlsbad, California

MaxCyte's chief executive Doug Doerfler will present the CARMA pipeline on Wednesday, 2 October

BIO Investor Forum

22-23 October, San Francisco, California

Doerfler will present to attendees on the CARMA pipeline

Society for Immunotherapy of Cancer

6-10 November, National Harbor, MD

Director of technical operations, Robert Keefe, will present a poster titled: "Single-day CAR manufacturing platform using mRNA and Flow Electroporation Technology" on November 9

BIO-Europe 2019

11-13 November, Hamburg Germany

Doerfler will present to attendees on the CARMA pipeline

Price: 210

Market Cap: £160.83 m

1 Year Share Price Graph



Share Information

Code: MXCT

Listing: AIM

52 week High Low
210.6 95

Sector: Pharma & Biotech

Website: www.maxcyte.com

Company Synopsis:

We are a U. S. -based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).